“It just looked like a pimple that was about to get a head on it,” she said. “I tried to squeeze it, but nothing happened.” After two weeks, the spot had not disappeared, instead growing about 10 times in size until it was as large as his nostril. “It went from a dot to 10 millimetres long in two weeks,” Nazifovski said. “It grew even more – it appeared on the whole left side of his nostril.” Concerned, the 24-year-old sought advice from his local GP, who told him the dot was an infected boil and gave him antibiotics. However, that advice was wrong.
Credit: The Wistar Institute
PHILADELPHIA and MELBOURNE, Australia (May. 17, 2021) A team of scientists from The Wistar Institute in Philadelphia and the Peter MacCallum Cancer Center in Melbourne, Australia, discovered a new checkpoint mechanism that fine-tunes gene transcription. As reported in a study published in
Cell, a component of the Integrator protein complex tethers the protein phosphatase 2A (PP2A) to the site of transcription allowing it to stop the activity of the RNA polymerase II enzyme (RNAPII). Disruption of this mechanism leads to unrestricted gene transcription and is implicated in cancer.
The study points to new viable opportunities for therapeutic intervention demonstrating the anti-cancer effect of a new combination treatment in preclinical models of solid and hematopoietic malignancies.
Graphic warning: images may disturb some readers
When a young Melbourne man spotted a dot on his nose, a pimple seemed to be the most obvious diagnosis.
However, in a matter of weeks, the dot ballooned in size - and it turned out to be cancer.
Josh Maschewski, 24, and his partner Ayshe Nazifovski, 30, are now warning people to remain vigilant if they see an obscure spot on their face.
Speaking to 9news.com.au, Ms Nazifovski said her partner developed the spot on his left nostril at the end of February, which looked just like a pimple - but was far from it.
(ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne to advance its CAR-T programs utilising the OmniCAR platform.
The new program builds on the company’s existing research agreement with Peter Mac focusing on cell therapy enhancement programs.
The new agreement expands this relationship to include the development of the OmniCAR platform.
The company said it is developing three OmniCAR programs internally, including next-generation CAR-T therapies for acute myeloid leukaemia (AML), Her2+ solid tumours and glioblastoma multiforme (GBM).
Prescient said it is developing OmniCAR as a CAR-T platform, capable of being deployed by other CAR-T and oncology companies under licence to advance their own programs.
Prescient Therapeutics signs CAR-T agreement with Peter Mac Cancer Centre
The new CAR-T agreement for the OmniCAR platform adds to Prescient’s existing and related research program with Peter Mac into Cell Therapy Enhancements. OmniCAR seeks to make CAR-T more controllable and adaptable.
Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with world-renowned Peter MacCallum Cancer Centre to advance its next-generation CAR-T program utilising the OmniCAR platform.
Prescient has an existing research agreement with Peter Mac focusing on Cell Therapy Enhancement program, which seeks to improve current generation CAR-T approaches.
This new agreement expands the Prescient and Peter Mac research relationship to include development of the next generation OmniCAR platform.